Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Repetitive Versus Deep Transcranial Magnetic Stimulation for Major Depression

NCT05902312 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2024-01-01
Last updated
2025-07-17

Condition(s) studied

Major Depressive Disorder

Investigational drug(s) / intervention(s)

transcranial magnetic stimulation

transcranial magnetic stimulation: Participants will receive either rTMS or dTMS

Study summary

The goal of this randomized controlled trial is to he effectiveness of two different TMS techniques in TRD, repetitive TMS (rTMS) and deep TMS (dTMS). The main questions it aims to answer are:

type of study: clinical trial participant population/health conditions : Major Depressive Disorder To assess the superiority of dTMS over rTMS in TRD To evaluate the predictive capacity of scalable candidate biomarkers Participants will be randomly allocated to one of the two intervention groups (rTMS or dTMS).

Eligibility

Sex
ALL
Min age
21 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Major Depressive Disorder, at least moderate intensity, single or recurrent episode * HRSD-17 score of at least 18 * No improvement to at least two adequate courses of antidepressants (based on the ATHF) or were unable to tolerate at least two separate trials of antidepressants of inadequate dose and duration * On a stable antidepressant regimen for the past four weeks before screening * Patients with a chronic depressive episode \>2 years and who have previously received ECT or ketamine will be eligible to participate Exclusion Criteria: * Having previously received TMS; * Substance use disorder within the last three months * Diagnosis of bipolar or psychosis spectrum disorder * Anxiety or personality disorder that is assessed by a study investigator to be the primary cause and causing greater impairment than MDD * Concomitant major unstable medical or neurological illness * Intracranial implant, cardiac pacemaker or implanted medication pump * Significant laboratory abnormality; * Active suicidal intent * Pregnancy * If participating in psychotherapy, must have been in stable treatment for at least three months before entry into the study, with no anticipation of change * Currently taking more than the equivalent of 2 mg of lorazepam of a benzodiazepine daily or any dose of an anticonvulsant due to the potential to limit TMS effectiveness

Primary outcome measure(s)

  • Hamilton Rating Scale for Depression-17 (HRSD-17) — Baseline to Week 6
    score change. Higher score means worse outcome. (Min = 0, Max = 53)
  • Response (yes/no) on Hamilton Rating Scale for Depression-17 — baseline to Week 6
    Defined as a score reduction of 50% or more
  • Remission (yes/no) on Hamilton Rating Scale for Depression-17 — Week 6
    Defined as a score of 7 or less

Trial sites (1)

FacilityCityRegionStatus
CHUM Montreal Quebec
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05902312 on ClinicalTrials.gov ↗ ← All trials in Canada